PROVINCIAL FUNDING SUMMARY

Alecensaro (Alectinib) for Non-Small Cell Lung Cancer (first line) (pCODR 10125)

pERC Recommendation: Recommends with conditions
For further details, please see pERC Final Recommendation

Notification to Implement Issued by pCODR: August 10, 2018

This information is current as of October 1, 2020.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	May 1, 2019	Advanced non-small cell lung cancer - Laboratory confirmed anaplastic lymphoma kinase (ALK)-positive tumour defined as either IHC 3+ or FISH positive - ECOG 0-2 - First-line monotherapy - Second-line monotherapy for disease progression after prior platinum-based chemotherapy - Second-line monotherapy for disease progression on crizotinib, or in patients with intolerance to crizotinib - BC Cancer Compassionate Access Program (CAP) approval must be obtained - NOTE: Sequential ALK targeted therapies (e.g., crizotinib, ceritinib) is not funded after first-line alectinib
AB	Funded	Mar 1, 2019	For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy), or metastatic non-small cell lung cancer (NSCLC), who have disease progression on or intolerance to crizotinib.
SK	Funded	Feb 11, 2019	First-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). Eligible patients should have a good performance status and treatment should continue until disease progression or unacceptable toxicity.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
MB	Funded	May 31, 2019	For the first line treatment of patients with anaplastic lymphoma kinase (ALK) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). Patients should have a good performance status and treatment should continue until disease progression or unacceptable toxicity.
ON	Funded	Apr 17, 2019	Initial Criteria: For the treatment of anaplastic lymphoma kinase ("ALK") – positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients meeting ALL the following criteria; • Alectinib is used as first line treatment OR after experiencing disease progression or intolerance on crizotinib1, 2, 3; AND • Alectinib is used as monotherapy; AND • Patient has good performance status (ECOG ≤ 2). 1Patients who have progressed during or following first-line therapy with alectinib are not eligible to receive alectinib as a subsequent-line therapy. 2Time-limited funding will be considered case-by-case in patients with ALK-positive NSCLC who have progressed on chemotherapy and crizotinib OR crizotinib and an immune checkpoint inhibitor commenced prior to the public funding of alectinib. 3 Include details of the intolerance including the grade of toxicity and reasons why crizotinib was not able to be used. Exclusion criteria: • Alectinib will not be funded if the patient has experienced disease progression while on an ALK inhibitor other than crizotinib. • Alectinib will not be funded beyond third line. Public funding will be considered for only one of Alectinib (Alecensaro) OR Ceritinib (Zykadia) and vice versa. Recommended dose: 600 mg twice daily Renewal Criteria: Ongoing funding will be considered in patients who have not experienced disease progression or unacceptable toxicities to treatment with Alectinib. Approval duration of initial and renewal requests: 1 year
NS	Funded	Oct 3, 2019	For the first line treatment of patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). Patients should have a good performance status and treatment should be continued until disease progression or unacceptable toxicity.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
NB	Funded	May 16, 2019	For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer when used: • as first-line therapy, or • following disease progression on, or intolerance to, crizotinib. Renewal Criteria: • Written confirmation that the patient is responding to treatment. Clinical Note: • Treatment should be discontinued upon clinically meaningful disease progression or unacceptable toxicity. Claim Notes: • Requests for alectinib will not be considered for patients who experience disease progression on any ALK inhibitor other than crizotinib. • No further ALK inhibitor will be reimbursed following disease progression on alectinib. • Initial approval period: 1 year. • Renewal approval period: 1 year.
NL	Funded	Sep 27, 2019	For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer when used as first-line therapy, OR following disease progression on, or intolerance to, crizotinib. Renewal Criteria: Written confirmation that the patient is responding to treatment. Clinical Note: 1. Patients must have a good performance status 2. Treatment should be discontinued upon clinically meaningful disease progression or unacceptable toxicity.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.